Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
about
Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial ResistanceDifferent Poses for Ligand and Chaperone in Inhibitor-Bound Hsp90 and GRP94: Implications for Paralog-Specific Drug DesignA purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90)Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell lossDivergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitorAnti-malaria drug blocks proteotoxic stress response: anti-cancer implications.Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects.Selection and Characterization of Single Chain Antibody Fragments Specific for Hsp90 as a Potential Cancer Targeting Molecule.Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathiesHeat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsisA systematic protocol for the characterization of Hsp90 modulators.Heat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells.Dynamics of conserved waters in human Hsp90: implications for drug designHeat shock proteins: essential proteins for apoptosis regulation.Targeting Hsp90: small-molecule inhibitors and their clinical development.A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.Hsp90, an unlikely ally in the war on cancer.The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-aminesCurrent concepts in clinical radiation oncology.Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.Heat shock proteins and kidney disease: perspectives of HSP therapy.A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica.
P2860
Q26864290-1E06CCDA-2F7B-4062-85A1-762E944D1751Q27654646-633EC30D-5DCB-474A-84CF-352D344DAEF2Q28533944-1CEF0F6C-C917-4671-981F-822BBB46C924Q28538890-1A3741A3-6D39-4811-B82F-A057E55B5F23Q33330693-0B4CCC36-DA66-4C95-A52C-0C367F2BEF8CQ34072984-12FF83FC-10CB-43C0-A772-CB5A98814B97Q34096497-A450049F-B917-48DE-ADDF-7BAD59306D2BQ34282588-CF75775D-8D1C-481A-9AD5-B23F286D0798Q34382527-37859491-DAA0-43D2-AB2C-6C38093E6C86Q35044051-806FBE53-0B53-4044-91B1-6AD52126A875Q35755602-85392B08-978E-4CC5-8552-4D1BD9E76813Q35839667-1072DF1E-8391-4A90-A8E1-A850E8317032Q36013740-F3A4FDEE-DD96-4998-8565-C3B573A79D83Q36201554-875C3A8E-9BD0-4726-8759-A87541768F59Q36588726-DDD63DF7-7036-4265-B523-15F73BA8FFA7Q36980659-38492ABD-DC0E-4018-A110-18751D38FAA5Q37081794-4D4B0043-EA77-4F0B-B379-BAB051B6A653Q37222845-6F6BACED-84B1-4974-A5B3-540E6730E273Q37245887-F1B1CBC3-403F-4807-A438-270C682402CDQ37274497-6692A279-6C35-47AA-87F3-A72DD086209DQ37304764-4D17C2FC-510E-4EDA-B5DD-9B3B4C74607AQ37319750-4E6B7348-3404-4B5C-B3FC-21333F661F2BQ37603804-AC5E5A88-AFF7-4E53-9635-5A11A1280A03Q37622446-83E08CDC-C8AB-44E2-A15D-4EE0833E3512Q39242393-7E99F633-4B52-4BF5-8FA8-889DB26B25E7Q39586391-605AF1B2-1110-4C1E-98F5-0BBED47538CAQ40613223-3958F5AC-5BFD-40C2-804B-0DE7583B9172
P2860
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@ast
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@en
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@nl
type
label
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@ast
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@en
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@nl
prefLabel
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@ast
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@en
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
@nl
P2093
P1476
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents
@en
P2093
David Solit
Eloisi Caldas Lopes
Gabriela Chiosis
P304
P577
2006-06-01T00:00:00Z